Zhang and collaborators (114) reported that Sirt1 is a direct target of miR-22, and their expression is antagonistic, so miR-22 improves radiosensitivity to breast cancer cells by targeting Sirt1. This evidence concerns the gene SIRT1 and breast cancer.